In prostate cancer samples, we found that 43–47% of DTCs from patients with no evidence of disease after many years of relapse-free follow-up showed NR2F1 mRNA upregulation, compared with 10% of the DTCs in advanced prostate cancer [6]. The gene discussed is NR2F1; the disease is prostate carcinoma.